RETURN TO YOU

Keep recurrent C. diff infection from coming back with
one dose of REBYOTA^®

What is REBYOTA?

REBYOTA (“REE-bye-oh-ta”) is the first and only single-dose, FDA-approved microbiome-based therapy to keep recurrrent C. diff infection from coming back, after you’ve taken antibiotics.¹

Learn more about REBYOTA

There are multiple location options for administration of REBYOTA

REBYOTA can be administered in your doctor’s office or right in your home—in one dose, one visit. Please speak with your doctor about which option is best for you and they will help get you started.

REBYOTA administration  in your doctor’s office

REBYOTA can be administered right in your doctor’s office once you’ve completed your course of antibiotics. After administration, there is a 15-minute wait period, after which you can go home.

REBYOTA @ Home

If you are unable to receive REBYOTA in your doctor’s office, you may benefit from the option of administration via home health in the comfort of your home.

Getting REBYOTA

REBYOTA patient stories

Watch patients tell their stories of how REBYOTA helped  keep recurrent C. diff infection from coming back.

It has been six months since REBYOTA. I have not had another recurrence.

– Heather, Actual REBYOTA Patient

Most common side effects may include stomach pain,  diarrhea, bloating, gas, and nausea.¹
For more information, please talk to your doctor and see full Prescribing Information.  Heather was compensated for her time. Individual results may vary.

See more patient stories

REBYOTA support and resources

Access REBYOTA support information to learn more about recurrent C. diff infection, get caregiver tips, and to download a diary to keep track of your journey.

REBYOTA support and resources

REBYOTA is the first and only single-dose, FDA-approved microbiome-based therapy to keep  recurrent C. diff infection from coming back, after you’ve already taken antibiotics.¹

About recurrent C. diff infection

Sign up for more information

Receive additional information and resources to help you through your C. diff infection journey.

First Name*(Required)

Last Name*(Required)

Email Address*(Required)

Phone Number

What’s your experience with C. diff infection?*(Required)

What’s your experience with C. diff infection?*

I currently have a C. diff infection

I had a C. diff infection within the last year

I am a C. diff patient caregiver

I’m interested in learning more about C. diff

*Required field.

By providing the information requested, I am confirming that I am a US resident, 18 years of age or older, and am giving Ferring permission to store and use the information that I have provided. I understand and agree that my information will be used by Ferring (or companies working on Ferring’s behalf) to contact me by telephone, email, or mail to provide me with information that may be of interest to me or to invite me to participate in research, educational, and marketing initiatives. I understand that my information will be treated as described in Ferring’s Privacy Notice, which provides details about my privacy rights. Also, I understand that I may opt out of the database at any time by making the request at Data Subject Form or by calling 1-888-FERRING, Monday through Friday, 8 _AM to 7 _PM ET to speak to a representative or leave a voicemail. This statement may be updated from time to time.

Reference

REBYOTA. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.

Please see Important Safety Information and full Prescribing Information

INDICATION

REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.

Important Safety Information

You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
You should report to your doctor any infection you think you may have acquired after administration.
REBYOTA may contain food allergens.
Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
REBYOTA has not been studied in patients below 18 years of age.
Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.

Please click to see the full Prescribing Information.

RETURN TO YOU

Keep recurrent C. diff infection from coming back with one dose of REBYOTA®

There are multiple location options for administration of REBYOTA

REBYOTA administration in your doctor’s office

REBYOTA @ Home

REBYOTA patient stories

REBYOTA support and resources

REBYOTA is the first and only single-dose, FDA-approved microbiome-based therapy to keep recurrent C. diff infection from coming back, after you’ve already taken antibiotics.1

Sign up for more information

Reference

Please see Important Safety Information and full Prescribing Information

INDICATION

Important Safety Information

You are leaving REBYOTA.com

Keep recurrent C. diff infection from coming back with
one dose of REBYOTA^®

REBYOTA administration  in your doctor’s office

REBYOTA is the first and only single-dose, FDA-approved microbiome-based therapy to keep  recurrent C. diff infection from coming back, after you’ve already taken antibiotics.¹